ArticleActa diabetologica2026
Methodological considerations in the UK Biobank diabetes‑tinnitus study.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tinnitus is a common and often debilitating condition that substantially affects quality of life. While diabetes has been suggested as a potential risk factor, the relationship remains poorly understood, particularly in large population-based settings where classification of diabetes type often relies on algorithms rather than confirmatory biomarkers. The recent UK Biobank study by Ji and colleagues addresses this gap by reporting that type 2 diabetes is associated with higher tinnitus prevalence. While the study benefits from a large sample and systematic examination of diabetes-related factors, two methodological concerns warrant consideration before the findings are interpreted as robust evidence. First, diabetes type was determined using algorithmic classification without confirmatory biomarkers such as autoantibodies or C-peptide. Second, the analytical strategy treated age as a simple covariate, implicitly assuming that the diabetes-tinnitus association remains constant across the entire 40-70 year age range. While the study offers valuable hypothesis-generating data, these methodological considerations suggest that the reported associations should be interpreted cautiously until confirmed by biomarker-validated phenotyping and more flexible analytical approaches that account for age-related heterogeneity.
Indexed as
Identifiers
42550221What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.